Medtronic commences pivotal trial for Next-Generation CGM sensor
Category: #health  By Mateen Dalal  Date: 2019-06-10
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medtronic commences pivotal trial for Next-Generation CGM sensor

Next-generation Guardian CGM is designed to lower sensor calibrations, improve and refine the accuracy and the overall performance of the system

World’s largest company for medical devices, Medtronic recently announced that it has started a pivotal trial of the company’s next-generation Guardian (TM) continuous glucose monitoring (CGM) sensor.

It has specifically been designed to lower sensor calibrations, improve and refine the accuracy and the overall performance of the system, sources familiar with the matter informed.

According to sources, over the span of seven days the next-generation CGM Sensor, in around 460 participants aged from two to 80 years old diagnosed with type one and two diabetes, shall be studied under the prospective trial. Sensor wear locations along with days and times when the testing will be done will be assigned to the participants randomly.

Medtronic’s Diabetes Group Research and Development vice president, Ali Dianaty believes that it is essential for the calibration to take place on the first day of wear because it improves the performance since day one.

Dianaty adds that research has depicted the performance for day one is crucial in the sense that it keeps the patients safe and protected in Auto Mode, or hybrid close loop which provides maximum Time in Range on insulin therapy for patients, as previously learned from real world experiences.

The vice president expressed his excitement over the next-generation CGM sensor because of its design, that needs calibration done on its first day which in turn results in 95% reduction of fingersticks as compared to existing CGM.

Emory University’s clinical associate professor, Dr. Bruce Bode, called the trial a positive step towards improving the experience with hybrid close loop systems of Medtronic integrated with sensors that primarily focus on the experience a patient gets.

Dr. Bode said the advancements are informed with the vigorous use of Medtronic therapies in the real world. It lays an emphasis on making sure that apart from delivering the best results, the technologies focuses mainly on ease of use.

Source Credit- http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2400976

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More

More News By Mateen Dalal

Dermtech signs a commercial & medicare advantage coverage agreement
Dermtech signs a commercial & medicare advantage coverage agreement
By Mateen Dalal

DermTech Inc., a San Diego based biotechnology company that is involved in precision dermatology, has recently announced signing a contract with a regional health plan to develop its gene expression based PLA (Pigmented Lesion Assay) for prior detect...

CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
CoImmune Inc. inks all-stock merger deal with Formula Pharmaceutical
By Mateen Dalal

The merger will bring two therapeutic immune-oncology platforms together Focus shall be placed over Phase 1 and Phase 2 trials of CAR-CIK and CMN-001 respectively U.S.-based bioscience firm CoImmune, Inc., announces partnership with Formula Phar...

Adverum reviews recent business progress and unveils its 2020 outlook
Adverum reviews recent business progress and unveils its 2020 outlook
By Mateen Dalal

Adverum Biotechnologies, a California based biotech company, has reportedly announced that it has examined its recent business & development progress. The company has also unveiled its outlook for 2020. Leone Patterson, president and chief execu...